
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
3
A Shot in the Arm to Traditional Vaccine Trial Strategy
4
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
5